ライフサイエンスコーパス: quality-adjusted life year

1 cost-effectiveness ratio of pound20 000 per quality-adjusted life-year).

2 an therapy vs warfarin therapy (7.94 vs 7.54 quality-adjusted life years).

3 $10 239), with greater utility (3.15 vs 2.47 quality-adjusted life years).

4 care resources, and impact on health status (quality-adjusted life-years).

5 imary outcome was cost (2014 US dollars) per quality adjusted life year.

6 62%, to $5459 per year, to reach $100000 per quality-adjusted life year.

7 and 82% of cases at a threshold of $100,000/quality-adjusted life year.

8 cost-effectiveness ratio of - pound1,542.16/quality-adjusted life year.

9 cost-effectiveness threshold of $100 000 per quality-adjusted life year.

10 ratio of SDS versus TAU was pound43 603 per quality-adjusted life-year.

11 cost-effective at pound20 000 ($26 600) per quality-adjusted life-year.

12 f statin plus PCSK9i therapy was $337729 per quality-adjusted life-year.

13 mphotericin plus flucytosine was $23 842 per quality-adjusted life-year.

14 ectiveness ratio was $782,598 per additional quality-adjusted life-year.

15 tive at a willingness to pay of $100 000 per quality-adjusted life-year.

16 We calculated cost per quality-adjusted life-year.

17 t a willingness-to-pay level of $100,000 per quality-adjusted life-year.

18 ness-to-pay threshold was set at $50 000 per quality-adjusted life-year.

19 willingness-to-pay threshold of $109 000 per quality-adjusted life-year.

20 ntal cost-effectiveness ratio of $39 400 per quality-adjusted life-year.

21 tal cost-effectiveness ratio of $189,000 per quality-adjusted life-year.

22 I+BB and ACEI+BB versus ACEI was <$1,500 per quality-adjusted life-year.

23 y accepted societal threshold of $100000 per quality-adjusted life-year.

24 llingness-to-pay threshold of AUS$30 000 per quality-adjusted life-year.

25 Effectiveness was estimated as Quality-Adjusted Life Years.

26 tant S aureus infections and improvements in quality-adjusted life years.

27 iency ratio was estimated to be euro7770 per quality-adjusted life-years.

28 very 6 months for year 2) and gaining 0.0011 quality-adjusted life-years.

29 mature deaths and 87.1% of gains in terms of quality-adjusted life-years.

30 as well as the loss of both productivity and quality-adjusted life-years.

31 ality of life measured in net life-years and quality-adjusted life-years.

32 90 premature deaths from AAA and to gain 577 quality-adjusted life-years.

33 er years [standard error (SE) 0.007]), fewer quality-adjusted life years (0.023 [SE 0.007] fewer usin

34 AS compared with Current Pace was $68900 per quality-adjusted life-year ($38300 for black MSM) and wa

35 ffectiveness ratio of $45,320 per additional quality-adjusted life year (= $516/0.011).

36 ctiveness at a willingness to pay of $50,000/quality-adjusted life year (86%; PCa, 2%; Ca, 12%).

37 significant differences in survival time and quality-adjusted life years according to all assessed ba

38 ving usual coverage lived an average of 9.46 quality-adjusted life years after their event and incurr

39 our willingness-to-pay threshold is $50,000/quality-adjusted life year and 82% of cases at a thresho

40 atment strategy resulted in 9.27 per-patient quality-adjusted life years and $304,800 per patient lif

41 tment strategy resulted in 11.48 per-patient quality-adjusted life years and $365,948 per patient lif

42 Utility and effectiveness were measured in quality-adjusted life years and benefit in US dollars.

43 The net effects of niacin-laropiprant on quality-adjusted life years and hospital care costs (201

44 iving full coverage lived an average of 9.60 quality-adjusted life years and incurred costs of $167,4

45 izumab therapy compared with PRP were $55568/quality-adjusted life-year and $662978/quality-adjusted

46 en current conditions was >$43.7 million per quality-adjusted life-year and using only fidaxomicin wa

47 nt, with a small consequential loss of 0.005 quality-adjusted life-years and extra costs of $800 for

48 l achieved an overall lifetime gain of 0.034 quality-adjusted life-years and savings of over $4,000 p

49 t in greater quality-adjusted survival (0.14 quality-adjusted life years) and less resource use ($401

50 DR-TB with FQN resistance, TB-related death, quality-adjusted life years, and health system costs.

51 undertaken to determine the lifetime costs, quality-adjusted life years, and incremental cost-effect

52 The model outputs included lifetime costs, quality-adjusted life years, and lifetime risk of develo

53 cases, 263,000 more fractures, 145,000 more quality-adjusted life-years, and expenditure savings of

54 cture; long-term outcomes, such as survival, quality-adjusted life-years, and functional status; rece

55 Calculated outcomes included survival, quality-adjusted life-years, and incremental cost-effect

56 At a threshold of $100 000 per quality-adjusted life year, apixaban provided the greate

57 cost-effectiveness threshold of $100 000 per quality-adjusted life year, apixaban seems to be the opt

58 Lifetime net quality-adjusted life-years are positive for most adults

59 ompeting strategies still cost >$200 000 per quality-adjusted life-year as that risk approached 99%.

60 Utility values were based on quality-adjusted life years associated with visual acuit

61 eights at baseline and 1 month and projected quality-adjusted life-years assuming a linear decline ov

62 remental cost-effectiveness ratio = $197,906/quality-adjusted life year at mean age = 85 yr).

63 Warfarin therapy had the lowest discounted quality-adjusted life years at 4.55, followed by dabigat

64 tio for PCI compared with MT was $17 300 per quality-adjusted life-year at 2 years and $1600 per qual

65 -adjusted life-year at 2 years and $1600 per quality-adjusted life-year at 3 years.

66 6 months for year 2 strategy gaining 0.0006 quality-adjusted life-years, but cost $4 913 599 per qua

67 creased lifetime costs by $419 and increased quality-adjusted life years by 0.16.

68 analysis, universal decolonization increased quality-adjusted life years by 1.06% (95% CI, 1.02-1.09)

69 increased costs by $53 (CI, $3 to $156) and quality-adjusted life-years by 0.119 (CI, 0.017 to 0.378

70 is the preferred strategy at less than $150/quality-adjusted life year compared with the treat all s

71 ($7.3-$10.9 million) and health gains >2600 quality-adjusted life-years could be achieved from reins

72 For the entire cohort, a total of 736 quality-adjusted life-years could be gained were treatme

73 lar disease events and save 2.8 million more quality-adjusted life-years, despite using 6% fewer medi

74 tions are described and explained, including quality-adjusted life-years, disability-adjusted life-ye

75 Changes in quality-adjusted life-years, disability-adjusted life-ye

76 ficiency, as demonstrated by a high cost per quality-adjusted life-year, especially in nonsmokers.

77 urvival, health-related quality of life, and quality-adjusted life year expectancy of cancer patients

78 herapy is estimated to provide an additional quality-adjusted life year for $337729 .

79 Treatment before LT yielded more quality-adjusted life year for less money than treatment

80 short-term analysis and as incremental cost/quality-adjusted life year for the long-term model.

81 ICU effectiveness was measured by cumulative quality-adjusted life years for 5 years after ICU discha

82 The quality-adjusted life-year gain per patient was 0.11 (P<

83 $5,564 to $8,092) per patient, and the mean quality-adjusted life-year gain was 0.31 (95% CI, 0.27 t

84 base-case analysis, the incremental cost per quality-adjusted life year gained by adding tomosynthesi

85 With willingness-to-pay threshold per quality-adjusted life year gained ranging from $0 to $50

86 remental cost-effectiveness ratios (cost per quality-adjusted life year gained) from the societal per

87 ained cost-effective (less than $100 000 per quality-adjusted life year gained) over a wide range of

88 ness-to-pay threshold (approximately $83 000/quality-adjusted life year gained); extension to age 22

89 Outcomes were incremental cost per quality-adjusted life year gained, asthma control (ACQ s

90 3 063, $111 465, and $140 557 per additional quality-adjusted life year gained, respectively.

91 -effectiveness ratio as measured by cost per quality-adjusted life year gained.

92 cremental cost-effectiveness ratio of $9,565/quality-adjusted life year gained.

93 the CDR 2+ strategy costs more than $125 000/quality-adjusted life year gained.

94 emental cost-effectiveness ratio of $473,400/quality-adjusted life year gained.

95 ,060-equivalent to GDP per capita in Goa-per quality-adjusted life year gained.

96 eatments produces a mean ICER of pound19,850/quality-adjusted life years gained compared to current t

97 ncrease cost-effectiveness (ICER pound15,090/quality-adjusted life years gained).

98 nt Staphylococcus aureus infections averted, quality-adjusted life years gained, and incremental cost

99 cost-effectiveness of TAVR was $116,500 per quality-adjusted life-year gained ($99,900 per life-year

100 atios (ICERs) in 2013 Australian dollars per quality-adjusted life-year gained (QALYG).

101 and incremental cost-effectiveness ratio per quality-adjusted life-year gained 36 months after treatm

102 fectiveness ratios <$10 000 per life-year or quality-adjusted life-year gained across a broad range o

103 $5760 per month, tolvaptan cost $744 100 per quality-adjusted life-year gained compared with standard

104 ratios (ICERs) were at least US$970 000 per quality-adjusted life-year gained for all four strategie

105 inal number needed to treat for 10 years per quality-adjusted life-year gained of 108.

106 at a number needed to treat for 10 years per quality-adjusted life-year gained of 35.

107 inal number needed to treat for 10 years per quality-adjusted life-year gained of 68.

108 life expectancy to 12.3 years, for $226,000/quality-adjusted life-year gained versus OHT.

109 The incremental cost per quality-adjusted life-year gained was $9333 (95% CI 3862

110 se that progressed more slowly, the cost per quality-adjusted life-year gained was even greater for t

111 Costs per quality-adjusted life-year gained were $154 700 to follo

112 fectiveness ratio was favorable ($16 537 per quality-adjusted life-year gained) and remained <$20 000

113 Cost-effectiveness (incremental cost per quality-adjusted life-year gained) was evaluated from a

114 expectancy to 8.5 years, and costs <$100,000/quality-adjusted life-year gained, relative to inotrope-

115 This strategy costs $202,000/quality-adjusted life-year gained, relative to inotrope-

116 at a predefined threshold of pound20 000 per quality-adjusted life-year gained, was 75% for closed tu

117 to that of generic clopidogrel, cost $29,665/quality-adjusted life-year gained, with 99% of bootstrap

118 cells per muL is cost-effective at $900 per quality-adjusted life-year gained.

119 st-effectiveness ratio expressed as cost per quality-adjusted life-year gained.

120 e to assuming a lower willingness to pay per quality-adjusted life-year gained.

121 adjusted life-years, but cost $4 913 599 per quality-adjusted life-year gained.

122 0 200 per year of life gained or $61 889 per quality-adjusted life-year gained.

123 ment before transplant less than US $150 000/quality-adjusted life-year gained.

124 and numbers needed to treat for 10 years per quality-adjusted life-year gained.

125 $35663 (95% CI, cost savings to $235613) per quality-adjusted life-year gained.

126 n, overall survival gains (in life-years and quality-adjusted life-years gained), and costs of integr

127 gery in this population was 0.80 (0.12); the quality-adjusted life-years gained, 2.43 (1.87); and the

128 Benefits were measured in quality-adjusted life-years gained.

129 life-year gained) and remained <$20 000 per quality-adjusted life-year in most bootstrap replicates.

130 with CAC>0 was cost-effective (<$50 000 per quality-adjusted life-year) in this scenario, in 55-year

131 5% prediction interval: 82,000, 183,000) per quality-adjusted life-year, in comparison with the strat

132 willingness-to-pay threshold of $50 000 per quality-adjusted life year, LAA closure was cost effecti

133 , we nonetheless estimate a 95% reduction in quality-adjusted life-years lost with a switch to the co

134 reast cancer deaths averted, life-years, and quality-adjusted life-years); number of mammograms used;

135 The greatest gains in quality-adjusted life-years occurred when all 3 guidelin

136 dverse events in 6 months, and the costs per quality adjusted life-year of the two treatments.

137 year over targeted decolonization and 14,562/quality-adjusted life year over screening and contact pr

138 precautions, respectively, and saved $16,203/quality-adjusted life year over targeted decolonization

139 s in wP vaccine-related adverse effects, and quality-adjusted life-years owing to changing vaccine sc

140 justed life-years per 1000 treated versus 74 quality-adjusted life-years per 1000 treated by the trea

141 efit-based tailored treatment would save 159 quality-adjusted life-years per 1000 treated versus 74 q

142 ansplant, not better, or dead) and estimated quality-adjusted life-years post-transplant.

143 g a willingness-to-pay threshold of $100,000/quality-adjusted life year; pricing below $18,450/year i

144 cost-effectiveness target of pound36 000 per quality-adjusted life-year projected over 20 years.

145 Using these data the quality adjusted life years (QALY) lost from the IPD rem

146 The additional quality adjusted life years (QALY) with intervention was

147 We calculated the incremental cost per quality-adjusted life year (QALY) and varied model input

148 mparative effectiveness was measured in: (1) quality-adjusted life year (QALY) gain and (2) percent p

149 ness ratios (ICERs) in 2015 U.S. dollars per quality-adjusted life year (QALY) gained and number of f

150 The primary outcome was incremental cost per quality-adjusted life year (QALY) gained from each diagn

151 We determined the incremental cost per quality-adjusted life year (QALY) gained.

152 ros at 2013 value), life-years gained (LYG), quality-adjusted life year (QALY), and incremental cost-

153 cost-effectiveness threshold of pound20 000/quality-adjusted life year (QALY).

154 fferences in total lifetime cost of care and quality-adjusted life years (QALY).

155 compared with bevacizumab were $1110000 per quality-adjusted life-year (QALY) and $1730000 per QALY,

156 r assessment every 10 years was $111 600 per quality-adjusted life-year (QALY) compared with no asses

157 V cross-protection, the incremental cost per quality-adjusted life-year (QALY) gained by additional 9

158 er epidemiological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the

159 er epidemiological findings and the cost per quality-adjusted life-year (QALY) gained, as well as the

160 1 (95% credible interval 12 662-132 452) per quality-adjusted life-year (QALY) gained, pound372 207 (

161 rted; cost per life-year saved; and cost per quality-adjusted life-year (QALY) gained.

162 rred over FIT at a threshold of $100,000 per quality-adjusted life-year (QALY) gained.

163 willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY) gained.

164 D events prevented and incremental costs per quality-adjusted life-year (QALY) gained.

165 most favorable strategy in term of cost per quality-adjusted life-year (QALY) gained.

166 We compared prevalence-based quality-adjusted life-year (QALY) loss associated with V

167 Compared with no screening, mean cost per quality-adjusted life-year (QALY) of screening all admis

168 tudies reported a median ICER of $13 761 per quality-adjusted life-year (QALY) saved.

169 infarction, or stroke), incremental cost per quality-adjusted life-year (QALY), and total effect on U

170 n, ischemic stroke and cardiovascular death, quality-adjusted life-year (QALY), incremental cost-effe

171 a cost-effectiveness threshold of US$500 per quality-adjusted life-year (QALY), no change in policy w

172 ffectiveness ratios, expressed as dollar per quality-adjusted life-year (QALY), were calculated with

173 ost-effectiveness ratio (ICER) was <$100 000/quality-adjusted life-year (QALY).

174 -effectiveness ratios (ICERs) in dollars per quality-adjusted life-year (QALY).

175 tion to quality of life, costs, and cost per quality-adjusted life-year (QALY).

176 lated health care cost per life-year and per quality-adjusted life-year (QALY).

177 Most ratios fell below $50,000 per quality-adjusted life-years (QALY) (73%) and $100,000/QA

178 reening, the reference scenario saved 51,000 quality-adjusted life-years (QALY) and had an incrementa

179 an liver disease costs were used to evaluate quality-adjusted life-years (QALY) and incremental cost-

180 t-effectiveness ratios, measured in cost per quality-adjusted life-years (QALY) gained.

181 Quality-adjusted-life-year (QALY) will be estimated taki

182 projected to provide a lifetime gain of 0.32 quality-adjusted life-years ([QALY]; 0.41 LY) with 3% di

183 55-year-old patients (less than $100 000 per quality-adjusted life-year [QALY] gained), while contras

184 with the brief intervention ( pound2394 per quality-adjusted life-year [QALY]) and the 12-week progr

185 years) and was cost-effective (ICER = $1915/quality-adjusted life-year [QALY]).

186 LAAC was cost-effective at 7 years ($42,994/quality-adjusted life-years [QALY]), and NOACs were cost

187 Health outcomes were expressed as quality adjusted life years (QALYs) and direct healthcar

188 ates the expected lifetime medical costs and quality adjusted life years (QALYs) of hypothetical coho

189 Patients with a repair had an average of 35 Quality Adjusted Life Years (QALYs) per patient over 55

190 Quality adjusted life years (QALYs) were calculated (Eur

191 owed there to be a small benefit in terms of quality-adjusted life years (QALYs) (0.0325, 95% CI -0.0

192 We measured lifetime costs and quality-adjusted life years (QALYs) (both discounted at

193 cuity were used to calculate the increase in quality-adjusted life years (QALYs) 3 years after the pr

194 ytic model was developed to project lifetime quality-adjusted life years (QALYs) and costs for asympt

195 Lifetime quality-adjusted life years (QALYs) and costs were model

196 Effects were measured in quality-adjusted life years (QALYs) and incremental cost

197 mes included MI and stroke rates, discounted quality-adjusted life years (QALYs) and lifetime costs (

198 ure are subsequently converted into gains in quality-adjusted life years (QALYs) by applying National

199 ov model was developed to estimate costs and quality-adjusted life years (QALYs) comparing between th

200 SOF/SMV yielded lower costs and more quality-adjusted life years (QALYs) for the average subj

201 ime horizon to estimate costs (2016 US$) and quality-adjusted life years (QALYs) for treatment sequen

202 monitoring costs, disease-related costs, and quality-adjusted life years (QALYs) gained by preventing

203 , we calculated the total cost and number of quality-adjusted life years (QALYs) gained.

204 We estimated quality-adjusted life years (QALYs) lost based on publis

205 the incremental cost-effectiveness ratio of quality-adjusted life years (QALYs) of the different str

206 t-utility analysis estimating mean costs and quality-adjusted life years (QALYs) per patient from the

207 comes and were used to calculate the gain in quality-adjusted life years (QALYs) resulting from OOKP

208 the progression of DR and determined average quality-adjusted life years (QALYs) saved and average ad

209 Changes in operative capacity and national quality-adjusted life years (QALYs) were calculated.

210 LR produced 3.9 quality-adjusted life years (QALYs) while CLT had an add

211 Lifetime costs, quality-adjusted life years (QALYs), and incremental cos

212 rosimulation model projected lifetime costs, quality-adjusted life years (QALYs), and incremental cos

213 uded health benefits expressed as discounted quality-adjusted life years (QALYs), costs in U.S. dolla

214 Outcomes include quality-adjusted life years (QALYs), costs, and incremen

215 Quality-adjusted life years (QALYs), costs, and incremen

216 Corresponding increases in survival, quality-adjusted life years (QALYs), costs, and resultin

217 ming of treatment initiation on total costs, quality-adjusted life years (QALYs), HCV-related complic

218 Quality-adjusted life years (QALYs), total cost, disease

219 led asthma in terms of health care costs and quality-adjusted life years (QALYs).

220 ed up to 1 year postoperatively to calculate quality-adjusted life years (QALYs).

221 iopsy in order to maximize a patient's total quality-adjusted life years (QALYs).

222 visual acuity were used to derive costs and quality-adjusted life years (QALYs).

223 gated by comparing mean cumulative costs and quality-adjusted life years (QALYs).

224 d temozolomide resulted in increases of 0.13 quality-adjusted life-years (QALYs) and $80,000 per pati

225 Outcome Measures: Discounted quality-adjusted life-years (QALYs) and discounted costs

226 It is also unclear how they relate to quality-adjusted life-years (QALYs) and funding recommen

227 effectiveness outcome was the difference in quality-adjusted life-years (QALYs) between groups from

228 onsquamous NSCLC resulted in a gain of 0.011 quality-adjusted life-years (QALYs) compared with standa

229 A Markov model was built to evaluate quality-adjusted life-years (QALYs) for both treatment g

230 ous adverse events and subsequent costs, and quality-adjusted life-years (QALYs) for intensive contro

231 Quality-adjusted life-years (QALYs) for use in cost-util

232 age, and ethnicity, to estimate undiscounted quality-adjusted life-years (QALYs) gained and net healt

233 the treatment of cardiovascular disease, and quality-adjusted life-years (QALYs) gained by treating p

234 arkov) model to calculate costs incurred and quality-adjusted life-years (QALYs) gained following HCV

235 The respective number of quality-adjusted life-years (QALYs) gained in the test a

236 health benefit (NHB), which was measured as quality-adjusted life-years (QALYs) gained or lost by in

237 Quality-adjusted life-years (QALYs) gained, costs from t

238 nomic outcome of lifetime societal costs per quality-adjusted life-years (QALYs) gained.

239 ature were used to calculate the increase in quality-adjusted life-years (QALYs) in a hypothetical co

240 e horizon was one influenza season; however, quality-adjusted life-years (QALYs) lost due to death du

241 nd caregiver costs with primary outcomes and quality-adjusted life-years (QALYs) to assess cost-effec

242 k reduction of 50%), the incremental gain in quality-adjusted life-years (QALYs) was determined using

243 Quality-adjusted life-years (QALYs) were assessed using

244 onal Insurance Scheme, life-years (LYs), and quality-adjusted life-years (QALYs) were computed for th

245 In-trial quality-adjusted life-years (QALYs) were similar (2.28 v

246 Effectiveness was measured in quality-adjusted life-years (QALYs), and costs were meas

247 outcomes were the number of HIV infections, quality-adjusted life-years (QALYs), and costs.

248 Outcome Measures: Incremental costs, quality-adjusted life-years (QALYs), and incremental cos

249 ted costs (in 2015 U.S. dollars), discounted quality-adjusted life-years (QALYs), and incremental cos

250 ained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental

251 uded health benefits expressed as discounted quality-adjusted life-years (QALYs), costs in US dollars

252 We estimated mean life-years, quality-adjusted life-years (QALYs), costs per person, a

253 Hospitalizations, quality-adjusted life-years (QALYs), costs, and incremen

254 Outcome Measures: Life-years, quality-adjusted life-years (QALYs), costs, heart failur

255 Life-years (LYs), quality-adjusted life-years (QALYs), direct medical expe

256 in Outcomes and Measures: Lifetime costs and quality-adjusted life-years (QALYs), discounted at 3% an

257 me breast cancer deaths, life expectancy and quality-adjusted life-years (QALYs), false-positive mamm

258 Endpoints were survival, life expectancy, quality-adjusted life-years (QALYs), number and percenta

259 Quality-adjusted life-years (QALYs), total costs (in US

260 Effectiveness was measured in terms of quality-adjusted life-years (QALYs).

261 lth outcomes were measured in life-years and quality-adjusted life-years (QALYs).

262 survival benefit of 0.15 life-years and 0.11 quality-adjusted life-years (QALYs).

263 with a pathogenic variant, in life-years and quality-adjusted life-years (QALYs).

264 United States dollars) to the difference in quality-adjusted life-years (QALYs).

265 res: Average lifetime costs, life-years, and quality-adjusted life-years (QALYs).

266 mes were HIV incidence, mortality, costs and quality-adjusted life-years (QALYs).

267 s compared health and social care costs with quality-adjusted life-years (QALYs).

268 The primary outcome measure was quality-adjusted life-years (QALYs).

269 hTSH was more effective than THW in terms of quality-adjusted life-years (QALYs; +0.013 QALY/patient)

270 ed, change in HIV prevalence, and discounted quality-adjusted life years [QALYs]), and incremental co

271 creasing benefits (6.034 to 6.221 discounted quality-adjusted life-years [QALYs] per patient with mon

272 estimate the discounted cost, effectiveness (quality-adjusted life-years [QALYs]), and incremental co

273 to estimate health care costs and outcomes (quality-adjusted life-years; QALYs) using data from the

274 $50000/quality-adjusted life-year to $150000/quality-adjusted life-year range frequently cited as cos

275 y was associated with an average gain of 1.5 quality-adjusted life years relative to barbiturate coma

276 and dabigatran were $20 486 and $23 422 per quality-adjusted life year, respectively.

277 : $17,000, $23,000, $44,000, and $81,000 per quality-adjusted life year, respectively.

278 it was less effective (8.44, 8.54, and 8.59 quality-adjusted life years, respectively) and more cost

279 55568/quality-adjusted life-year and $662978/quality-adjusted life-year, respectively, over 2 years.

280 of long-term stroke care and an increase in quality-adjusted life-years, thereby supporting more wid

281 as given in this trial is within the $50000/quality-adjusted life-year to $150000/quality-adjusted l

282 added from a third to almost half a million quality-adjusted life-years to the US population.

283 effect was genuine, the incremental cost per quality-adjusted life year was pound56,811 in the base c

284 d exercise was pound156 per person; cost per quality-adjusted life-year was pound9549 with the EQ-5D

285 -adjusted life expectancy (defined as >/=0.1 quality-adjusted life-years) was projected in 832 patien

286 cost effectiveness ratio below $100,000 per quality-adjusted life year were considered cost effectiv

287 Quality-adjusted life-years were also calculated.

288 Changes in quality-adjusted life-years were assessed with utilities

289 quality-adjusted life expectancy reported as quality-adjusted life-years were calculated by a decisio

290 Quality-adjusted life-years were similar between the gro

291 Quality-adjusted life-years were virtually identical in

292 British pounds, pound) and health utilities (quality-adjusted life years) were used to calculate mean

293 alth service costs and benefits (measured as quality-adjusted life-years) were estimated.

294 ietal) perspective, assessed health gains in quality adjusted life years, were supported by academia,

295 follow up the entire cohort and $129 800 per quality-adjusted life-year when only smokers were includ

296 t-effectiveness ratio of PCI was $36 000 per quality-adjusted life-year, which was robust in bootstra

297 ated telemedicine in the ICU to extend 0.011 quality-adjusted life years with an incremental cost of

298 The discounted quality-adjusted life years with UDCA and OCA+UDCA were

299 equivalent utility (11.5 vs 11.4 discounted quality-adjusted life years) with lower total cost ($52.

300 its was within accepted US norms ($53925 per quality-adjusted life year, with 98% likelihood of meeti